Ethicscience

EthicScience fund raising campaign is a sponsorship program dedicated to support biomediacl research without supporting animal experimentation. This fund raising campaign was launched in 2013 and allowed us to collect more than 40 000 € for research so far. Several programs were selected including the development of a 3D human cell culture model for in-vitro lung cancer research, the development of an inhalation test to evaluate the in vitro toxicity of electronics cigarettes, or synthetic skin.

In full transparency, supporter of a more human biomedical research can choose to support the lobbying work of our staff or the scientific research thanks to EthicScience fund raising campaign.

New progarms are being selected for the 2018 edition : just send a presentation e-mail at contact@proanima.fr and we will contact you in return.

The collect for 2017 is going ! The financial boost will help fight against Parkinson decease (read below). If you want to make a donation please visit our Projet Parkinson page.

The research we support

Understanding Parkinson disease

brain1Jens Schwamborn and his team are conducting research on the Parkinson disease and other neurodegenerative disorders. They use the latest technologies based on bioingineering in order to find better solutions to help cure this serious disease. In France 150 000 people are affected by the desease. In vivo research has been failing in producing significant progress towards a better uderstanding of neurodegenerative disorders. It is urgent and necessary to support new tools that do not use animals thus allowing technical and scientific progress to become more used in the field of biomedical research.  Read more.


3D human cell culture model for in vitro lung cancer research

Cancer cell scientific 3d illustrationEach year, about 12 million people worldwide are diagnosed with cancer. However, despite the use of millions of animals and billions of dollars in cancer research, cure forthis devastating disease remains elusive.
With an overall drug approval of only 5% over the last 10 years, oncology is facing a dearth of new drugs. Analyses of clinical trials studies reveal that a large number of preclinical promising drug leads fail in late stages (70% failure in phase II) because of insufficient efficacy. Read more.


Development of an inhalation test to evaluate the in vitro toxicity of electronics cigarettes

fa9cc3_6b7bc0f729d245c4caabf31b2d1cc431[1]Despite a strong need both from authorities and consumers, to date there is no efficient assays to evaluate the short and long term toxicity of the electronic cigarette (e-cigarette). Read more.